Majeed Jibran, Turner Barbara S, Kelly Deirdre, Poon Chester, Thompson Julie A, Barrett John, Soff Gerald A
School of Nursing, Duke University, Durham, North Carolina.
Memorial Sloan Kettering Cancer Center, New York, New York.
J Adv Pract Oncol. 2022 May;13(4):382-391. doi: 10.6004/jadpro.2022.13.4.3. Epub 2022 Jun 21.
Cancer patients with venous thromboembolic (VTE) disease are complex, and many factors must be considered when initiating anticoagulation management. Clinical decision support systems can aid in decision-making by utilizing guidelines at the point of care.
The purpose of our project was to develop, implement, and evaluate an electronic clinical decision tool (CDT) utilizing evidence-based guidelines to aid in decision-making for adult oncologic patients who present with new VTE to symptom care clinics.
We compared a pre-intervention group of patients who were prescribed anticoagulation (n = 98) with two post-intervention groups: CDT applied (n = 96) and not applied (n = 46). Outcomes included whether the CDT anticoagulation recommendations were followed and if the tool was perceived to be helpful or improve confidence in initiating management for new VTE by the SCC advanced practitioners and physicians.
There was no significant difference between the pre- and post-intervention groups in how many of the CDT anticoagulation recommendations were followed (68.8% pre-intervention, 60.8% post-intervention tool applied, and 63.5% post-intervention tool not applied; χ [2, N = 161] = .921, = .631). However, the tool was found to be helpful and improved confidence of the providers in initiating management for new VTE (pre median = 3, interquartile range [IQR] = 2, 3.5; post median = 3, IQR 3, 4; = .033).
This CDT provided evidence-based anticoagulation recommendations for cancer-associated VTE and enhanced familiarity with the standard of care. Further development of the CDT will be required to account for situations that resulted in deviation from the recommendations.
患有静脉血栓栓塞(VTE)疾病的癌症患者情况复杂,在启动抗凝治疗管理时必须考虑许多因素。临床决策支持系统可通过在护理点利用指南来辅助决策。
我们项目的目的是开发、实施和评估一种电子临床决策工具(CDT),该工具利用循证指南来辅助为新出现VTE的成年肿瘤患者到症状护理诊所就诊时的决策。
我们将接受抗凝治疗的干预前患者组(n = 98)与两个干预后组进行比较:应用CDT组(n = 96)和未应用CDT组(n = 46)。结果包括是否遵循CDT抗凝建议,以及SCC高级从业者和医生是否认为该工具有助于或提高了对新VTE启动管理的信心。
干预前和干预后组在遵循CDT抗凝建议的数量上没有显著差异(干预前为68.8%,干预后应用工具组为60.8%,干预后未应用工具组为63.5%;χ[2, N = 161] =.921,P =.631)。然而,发现该工具是有帮助的,并提高了提供者对新VTE启动管理的信心(干预前中位数 = 3,四分位间距[IQR] = 2, 3.5;干预后中位数 = 3,IQR 3, 4;P =.033)。
该CDT为癌症相关VTE提供了循证抗凝建议,并提高了对护理标准的熟悉程度。需要进一步开发CDT以考虑导致偏离建议的情况。